SHTDF (Sinopharm Group Co) Change In Payables And Accrued Expense : $0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Change In Payables And Accrued Expense?

Sinopharm Group Co's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2024 was $0 Mil. It means Sinopharm Group Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Jun. 2024 .

Sinopharm Group Co's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0 Mil. It means Sinopharm Group Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Sinopharm Group Co Change In Payables And Accrued Expense Historical Data

The historical data trend for Sinopharm Group Co's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Change In Payables And Accrued Expense Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Sinopharm Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sinopharm Group Co Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

Sinopharm Group Co Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

SHTDY:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research • 06-17-2024

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014